Operator
Good morning, everyone. Welcome to DRI Healthcare Trust’s Conference Call on the tavapadon transaction.
Listeners are reminded that certain statements made in this conference call presentation, including responses to questions, may contain forward-looking statements within the meaning of the safe harbor provisions of Canadian provincial securities laws. Forward-looking statements involve risks and uncertainties, and undue reliance should not be placed on such statements. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements.
All statements regarding the tavapadon royalty assume closing of the transaction, which is subject, among other things, to approval of tavapadon by the U.S. Food and Drug Administration. Statements regarding expected deployment, adjusted EBITDA growth and the timing of royalties are forward-looking and assume, among other things, that tavapadon is approved by the FDA and successfully launched and that the U.S. net sales are in line with management’s expectations.
For additional information about factors that may cause actual results to differ materially from expectations and about material factors or assumptions applied in making forward-looking statements, please consult the MD&A for this quarter, the Risk Factors section of the annual information form and